Median (IQR) Rosiglitazone (n=34) Placebo (n=37)
Age in years 47 (44, 52) 52 (44, 54)
Men, N (%) 29 (85) 30 (81)
White, N (%) 19 (56) 17 (45)
CD4+ cell count, cells/mm3 596 (437, 706) 690 (422, 860)
Nadir CD4+ cell count, cells/ mm3 205 (98, 271) 123 (64, 247)
HIV-1 RNA <50 copies/mL, N (%) 28 (82) 29 (78)
Duration HIV diagnosis (months) 146 (122, 194) 170 (122, 231)
Duration on ART (months) 114 (96, 127) 105 (74, 123)
Duration on tNRTI (months) 65 (48, 59) 69 (24, 83)
Duration off tNRTI (months) 47 (14, 59) 42 (11, 64)
NNRTI at study entry, N (%) 15 (44) 14 (37)
PI at study entry, N (%) 19 (56) 23 (62)
Limb fat, grams 4695.9 (3643.6, 7758.3) 5966.7 (3514.3, 8434.7)
BMI, kg/m2 25.3 (22.5, 30.8) 25.8 (22.8, 27.9)
sTNFR-I, pg/mL 773.5 (597.0, 957.0) 701.5 (573.1, 891.0)
sTNFR-II, pg/mL 564.0 (232.0, 1247.0) 605.0 (315.0, 1208.2)
IL-6 , pg/mL 6.0 (2.0, 13.3) 6.0 (3.0, 10.5)
hs CRP, mg/L 7.6 (4.1, 18.1) 3.2 (1.2, 14.7)
F2 isoprostanes, ng/mL 0.032 (0.024, 0.043) 0.032 (0.027, 0.046)
mtDNA, copies/ cell 168 (143, 214) 205 (166,222)
# Significant difference between the groups (p=0.04)
Table 1: Baseline characteristics.
Goto home»